+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are studying patients with hypercholesterolaemia who either have a history of clinical atherosclerotic cardiovascular disease ASCVD or are at increased risk for a first ASCVD event. The trial aims to evaluate the effect on low-density lipoprotein-cholesterol LDL-C and the safety and tolerability of a fixed dose combination FDC of laroprovstatrosuvastatin compared to rosuvastatin alone. This is a Phase III randomized, double-blind, parallel-group study sponsored by AstraZeneca. Participants will be assigned to one of several groups receiving daily oral doses of laroprovstatrosuvastatin or rosuvastatin alone at different dose levels. Each laroprovstatrosuvastatin dose group is paired with a matching placebo to maintain blinding. The treatments are given daily over a period of 8 weeks to assess their effects on cholesterol levels. During the study, participants will undergo assessments to measure changes in LDL-C as the primary outcome at 8 weeks, along with secondary measures including Apo B, non-HDL cholesterol, and total cholesterol. Safety and tolerability will also be monitored throughout the treatment. Participants will have scheduled visits during the treatment period to ensure adherence and collect data, with the overall study completion projected by May 2027.

Age: 18Years - 130YearsAll GendersPhase 3
45 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
P

Actively Recruiting

Researchers are evaluating the effects of MAR001 compared to a placebo in adults with elevated triglycerides TG and remnant cholesterol RC. This Phase 2b, randomized, double-blind, placebo-controlled study aims to understand how MAR001 impacts TG levels in people with specific cholesterol conditions. The study includes two parts, focusing on different ranges of baseline triglyceride levels to assess the treatments effects. Participants in Part A with TG levels between 150 and 880 mgdL will receive one of three doses of MAR001 or placebo by subcutaneous injection every four weeks. In Part B, participants with higher TG levels between 450 and 2000 mgdL will receive a dose chosen based on Part A results, also by subcutaneous injection every four weeks. The study consists of a screening period lasting up to 8 weeks, a 24-week treatment phase, and a 12-week safety follow-up with two clinic visits. During the trial, participants will undergo assessments including clinical visits at specified weeks, laboratory tests, and monitoring for safety and treatment effects. Researchers will measure changes in triglyceride levels primarily at 12 weeks, along with secondary outcomes at various time points. The total participation duration includes screening, treatment, and follow-up periods, allowing for comprehensive evaluation of MAR001s impact and safety in this population.

Age: 18Years - 75YearsAll GendersPhase 2
55 locations